Silvestrini R, Daidone M G, Gasparini G
Cancer. 1985 Oct 15;56(8):1982-7. doi: 10.1002/1097-0142(19851015)56:8<1982::aid-cncr2820560816>3.0.co;2-i.
The relevance of cell kinetics of the primary tumor as a marker of biologic aggressivity was verified on a series of 258 patients with operable breast cancer without nodal and distant metastases, who underwent radical mastectomy without any other treatment until relapse. The cell proliferative rate, evaluated in vitro on fresh tumor material and expressed as 3H-thymidine labeling index, was found to be an important discriminant of metastatic potential. Patients with slowly proliferating tumors showed a higher probability of 6-year relapse-free survival in comparison to those with fast-proliferating tumors (80.5% versus 59.6%, P = 0.00004). This finding was true for premenopausal and paramenopausal (P = 0.00005) as well as for postmenopausal patients (P = 0.01). The kinetic variable was also a discriminant of 6-year survival for the overall series (P = 0.003) and for premenopausal and paramenopausal patients (P = 0.003) regardless of the type of treatment after relapse. These findings show the relevance of the kinetic variable as an important prognostic marker in breast cancer.
在一系列258例可手术切除且无淋巴结及远处转移的乳腺癌患者中,对原发肿瘤细胞动力学作为生物学侵袭性标志物的相关性进行了验证。这些患者接受了根治性乳房切除术,在复发前未接受任何其他治疗。通过对新鲜肿瘤组织进行体外评估,以3H-胸腺嘧啶核苷标记指数表示的细胞增殖率,被发现是转移潜能的重要判别指标。与快速增殖肿瘤患者相比,缓慢增殖肿瘤患者6年无复发生存概率更高(80.5%对59.6%,P = 0.00004)。这一发现对于绝经前和围绝经期患者(P = 0.00005)以及绝经后患者(P = 0.01)均成立。动力学变量也是整个系列患者6年生存率的判别指标(P = 0.003),对于绝经前和围绝经期患者同样如此(P = 0.003),且与复发后的治疗类型无关。这些发现表明动力学变量作为乳腺癌重要预后标志物的相关性。